+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 5Years - 60Years
All Genders
ID05675410

Comparing Standard Chemotherapy With or Without Immunotherapy and Radiation for Early Stage Classical Hodgkin Lymphoma in Children and Adults

Led by National Cancer Institute (NCI) · Updated on 2026-11-03

1875

Participants Needed

419

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are comparing the effects of adding immunotherapy drugs, brentuximab vedotin and nivolumab, to the standard chemotherapy treatment, with or without radiation, for patients diagnosed with early stage classical Hodgkin lymphoma stage I or II. This phase III trial aims to evaluate whether this combination improves survival and reduces side effects compared to standard treatment alone. The study includes both children and adults aged 5 to 60 years with newly diagnosed disease and measurable tumors. Participants first receive two cycles of the ABVD chemotherapy regimen. After treatment, imaging scans determine their early response, classifying them as rapid or slow responders and stratifying them by risk status favorable or unfavorable. Based on these factors, patients are assigned to one of eight different treatment arms involving variations of chemotherapy, immunotherapy, and involved-site radiation therapy. Treatments are given in cycles every 28 days, with some arms receiving additional cycles or radiation depending on response and risk. Throughout the trial, participants undergo regular imaging tests such as PET, CT, or MRI scans to monitor disease and treatment effects. Blood samples may also be collected. Following treatment completion, patients will be followed up with visits every 3 months for the first year, then every 6 months for two years, and annually up to 12 years. Researchers will assess outcomes including progression-free survival, overall survival, adverse events, patient-reported quality of life, fatigue, cognitive function, and long-term side effects.

CONDITIONS

Brief Title

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here